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PRACTICAL EVALUATION OF PSYCHOTROPIC MEDICATION
Lynne E. Turner
Western Michigan University, 2002
Surveys indicate that 25-40% of students with mental retardation or other
developmental disabilities receive one or more psychotropic medications, however,
almost nothing is known concerning how the effects of the medications are
monitored. Parents/guardians and teachers were interviewed to ascertain information
regarding current monitoring procedures in the home and in th� school setting.
Additionally information was gathered to ascertain their knowledge regarding: 1) the
reason for which their students were prescribed psychotropic medications; 2) the
behavioral domains that those medications are intended to affect, 3) the current status
of those behavioral domains, and 4) consumers' satisfaction with the pharmacological
intervention. The results suggest that both at home and at school there is a lack of
systematic monitoring of the effects of psychotropic medications, that
parents/guardians and teachers are not satisfied with the results produced by the
medication and that there is a general lack of knowledge about the rationale for the
prescribed medication and the side effects of these medications. Additionally, the
results suggest that both the parents/guardians and teachers h�ve a lack of knowledge
regarding the side effects of the medications prescribed.
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INTRODUCTION
Historical Background
In the early 1950s it was serendipitously discovered that chlorpromazine had a
calming effect on persons diagnosed as psychotic. Subsequently, chlorpromazine and
related drugs were widely prescribed for people with psychiatric disorders. These
drugs also were often prescribed for persons with developmental disabilities
(Caldwell, 1970). In 1958, Thomas Greiner predicted that, "In the years to come, the
retarded may claim an all-time record, of having the greatest variety and largest
tonnage of chemical agents shoveled into them" (p. 346). Data from subsequent
prevalence studies of psychotropic medication use by persons with disabilities during
the past 43 years have proven this prediction to be true (Singh, Ellis, & Wechsler,
1997). For example, Aman and Singh (1988) found psychotropic medication to be
one of the most prevalent forms of treatment for inappropriate behavior (e.g., self
injurious behavior, aggressive behavior) in persons with mental retardation.
A psychotropic medication is any drug that is prescribed with the intent of
improving mood, thought processes, or overt behavior (Poling & Byrne, 2000). The
use of psychotropic medication for treatment of behavioral problems in people with
mental retardation and other developmental disabilities (e.g., autism) has been
common and controversial for many years (Aman & Singh, 1988; Gadow & P6ling,
1988). Psychotropic medications historically were often used incautiously and at
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excessive doses in people with developmental disabilities. These problems were first
recognized over 20 years ago and at least partially corrected through legislations and
legal activity.
Regulations for Medication Usage in Institutions
Laws regulating the use of psychotropic medications in institutional settings,
which is where most people with developmental disabilities resided in years past,
emerged in 1971 with the landmark case of Wyatt v. Stickney. In this case, the federal
district court in Alabama ruled that conditions in three state hospitals for persons with
mental retardation violated the patients constitutional right to appropriate treatment.
That is, the court held that the patients were entitled to be free from unnecessary and
excessive medication and "unusual or hazardous treatment procedures" (as cited in
Singh, Guernsey, & Ellis, 1992). Further litigation followed and by 1985 relatively
clear standards for the use of psychotropic drugs in institutional settings were
established in most states (Kalachnik, 1994). Sprague (1982) published a careful
review of the relevant court cases and their resolutions. Kalachnik (1994) has
described these emergent standards set forth as a result of litigation, legislation, and
regulations as follows:
1. Psychotropic medications are to be prescribed and administered according
to the exercise of professional.judgment by a qualified professional.
2. Periodic attempts to reduce the drug dosage are required and the minimal
effective dose must be used.
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3. Appropriate evaluation procedures are to be used by an interdisciplinary
team to assess the effects of medications on target behaviors and to detect adverse
(i.e., side) effects.
4. Decisions conveying the continuation of, or decisions in, a patient's
medication has to be data based.
5. Written informed consent must be obtained from competent patients or
from a representative of incompetent patients before drugs are administered.
6. There must be an individualized treatment program that delineates specific
target behaviors for which the medication is prescribed.
7. There must be an integration of behavioral, educational, and medical
interventions.
Individuals Not Protected by Laws
When these standards are enforced, persons with developmental disabilities
are generally safe from harmful, ineffective, and unnecessary drug treatments. That
is, if the goals of drug treatment are clear and if decisions concerning the
effectiveness of medication are based on valid data, then pharmacological
interventions are being used in an appropriate and ethical manner (Poling, 1994;
Poling & Ehrhardt, 1999). At the present time, however, relatively few people with
mental retardation (or other developmental disabilities) reside in institutions.
Standards regulating the use of psychotropic drugs in institutions typically do not
apply to drug use in community setting.
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It is widely recognized that psychopharmacological treatments of childhood
emotional and behavioral disorders in school-aged children have increased
significantly over the past several years (Brown & Sawyer, 1998). Although the exact
percentage is unknown (Gadow, 1997), surveys indicate that 25-40% of students with
mental retardation or other developmental disabilities receive one or more drugs
intended to improve behavior (Reiss, 1998). Failure to monitor the effects of these
drugs adequately, which is necessary to optimize treatment for individual students, is
a serious and widespread problem (Gadow; Kollins, Ehrhardt, & Poling, 2000;
Poling, 1994).
Monitoring Medication in School-aged Children
The need for monitoring medications has been emphasized by professionals
for many decades. In 1971, the Report of the Conference on Stimulant Drugs stated:
"The decision to use drug treatment depends on the commitment to diagnose and to
monitor the response to the treatment in the best traditions of medical practice. When
there is informed parental consent, parents, teachers and professionals can collaborate
in organizing and monitoring treatment programs" (as cited in Weithorn & Ross,
1975 p. 60). Effective systematic monitoring may be accomplished in several ways.
These include the use of structured interviews, rating scales, direct observations of
behavior, and measures of performance, achievement, and activity (Brown & Sawyer,,
1998).
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Regardless of the system, judicious monitoring of the efficacy of psychotropic
medications prescribed for children with developmental disabilities is important for
several reasons (Brown & Sawyer, 1998). First, and foremost, the vast majority of
research on the effectiveness of psychotropic medication has focused mainly on
adults. The effects of psychotropic medication in children often differ from those
reported for adults (Barkley et al., 1990; Taylor, 1994). Thus, physicians need to
weigh carefully possible deleterious effects that could occur. Second, there is not a
specific psychotropic medication treatment for specific behavioral problems and few
indicators accurately predict children's responses to specific medication or dosages
(Taylor). Therefore, careful monitoring of children's responses to the different drugs
and different dosage levels is essential for identifying the most effective treatment.
Third, children are constantly changing as they mature, making monitoring of
medication effects imperative (Brown & Sawyer, 1998). That is, drug effects may
vary with development (Brown & Sawyer). Fourth, children are less capable then
adults of reporting the presence of adverse effects (Brown & Sawyer). Customarily,
adults will inform their physician when a medication is causing problems or is not
producing the desired effects. Children with developmental disabilities sometimes
lack the cognitive ability to recognize such problems, or lack the verbal capacity to
provide information about them. Furthermore, the approach of asking people about
how they have benefited from a medication does not accurately evaluate-the degree of
change because, "people simply do not remember how they were in the beginning"
(Streiner & Norman, 1995, p. 165). Finally, decisions to prescribe psychotropic
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medications or change dosage levels typically are based on informal global
assessments provided by parents or teachers (Brown & Sawyer; Gadow, 1982, 1983;
Singh & Winton, 1984; Fredericks & Hayes, 1995). Children's actual behavior may
have little influence on these decisions. Singh and Winton (1984), for example,
examined the correlation between behavioral observations of the target symptoms and
a physician's decision to change a patient's medication. Naturalistic observations
were made of a 15-year-old profoundly mentally retarded boy with self-injurious
behavior while he received medications to treat the self-injury. The results suggested
that the physician's decisions to change medication dosages were often not based on
related changes in the target behavior, but rather on the global impressions of the
ward staff. Interestingly, such physician practices appear not to have changed in 11
years, as these exact findings were replicated in another, more recent study
(Fredericks & Hayes).
Almost nothing is known concerning how the effects of psychotropic
medications typically are monitored in students with developmental disabilities.
There is, however, a sizable literature concerning students with a diagnosis of
attention deficit/hyperactivity disorder (ADHD). Parents usually depend on their
physician to diagnose ADHD and prescribe a medication for it without understanding
the consequences of administering such medication (Werry, 1999). Lamentably,
monitoring of the efficacy of psychotropic medications tends to be haphazard
(Gadow, Nolan, Paolicelli, & Sprafkin, 1991). Gadow et al. found that contacts
between physicians and classroom teachers and the use of well-validated assessment
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instruments often occur sporadically. Teachers were often uninformed about the
medication being used and physicians generally had limited knowledge about a
child's behavior at school. Furthermore, the decision to medicate and to continue
medication use typically is made by a pediatrician based on informal information
provided by parents.
Importance of School Involvement in Monitoring Medication
Children spend a significant portion of their lives in school, therefore, the
involvement of school personnel in monitoring drug effects would appear to be
essential to determine the efficacy of prescribed medications (Brown, Dingle, &
Landau, 1994; Gadow, 1982). That is, school personnel are in contact with children
for prolonged periods within a structured setting and have opportunities to observe
children in situations to which the parents may not have access (Gadow & Nolan,
1993). Thus, input from school personnel is invaluable for making decisions
regarding the effects of medications (Brown, Dingle, & Landau, 1994; Gadow, 1982,
1983; Weithom & Ross, 1975). It appears, however, that this does not occur
regularly. Two studies by Gadow (1982, 1983) found that school personnel
characteristically fail to play an important role in monitoring the effects of
psychotropic medications in students with mental retardation or other;developmental
disabilities. Teachers in early childhood special education programs and in
classrooms for trainable mentally retarded students who had at least one student
receiving medication for a behavior or a learning disorder were surveyed. The results
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indicated that teachers were often not involved in referral, diagnosis, or the
withdrawal of medication. Furthermore, 60% of the teachers reported drug effects
even though there were no systematic monitoring procedures in place and
standardized evaluation instruments were rarely used. Although teachers and other
school personnel are in a good position to collect data relevant to desired and adverse
effects of pharmacological treatments, that information typically is not systematically
shared with physicians (Brown & Sawyer, 1998; Gadow, 1982, 1983). Additionally,
special education teachers often make use of behavior-modification techniques than
can affect the same behaviors that are altered by medication (O'Leary & Pelham,
1978). Consequently, the teacher and the physician may have identical therapeutic
objectives, however, this is unknown to both parties involved (Gadow, 1982).
Moreover, school personnel may fail to obtain relevant data that could be collected
easily because they frequently are not informed about the desired effects of
medication. In fact, they may not even be informed that a given student is receiving
medication. That is, unless the child receives the medication at school, the parents are
not required by law to inform the school. Furthermore, parents are not required to
inform the school of any increases or decreases in the medication unless this affects
the dosage administered at the school.
The ADHD literature suggests that treatmel\t decisions regarding the use of
psychotropic medications in schools are based primarily on physician's reactions to
reports from parents, who may have little opportunity to observe a child's behavior at
school, where the problems that define ADHD are particularly likely to occur (Brown
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& Sawyer, 1998). Sleator and Sprague ( 1978) note the importance of this issue and
recommend that monitoring of drug effects must include reports from the teacher.
They further recommend that the medical profession should play an active role in
facilitating communication between physicians and school personnel. It appears,
however, that this has not occurred during the 24 years since their recommendation
appeared. Gadow (1997) noted "there was little evidence of interdisciplinary
collaboration or the use of standardized instruments to assess therapeutic or untoward
drug effects11 (p. 225). No studies have followed up on the findings of Gadow (1982,
1983), and in a 1997 article he lamented: "Unfortunately, there remains little
information on current practices in treatment evaluation for children with mental
retardation [who attend public schools]" (p. 225).
The purpose of the present study was to determine if parents and teachers of
students with mental retardation and/or autism are currently monitoring the effects of
psychotropi� medication(s) prescribed to their child/student and how much they know
regarding the reason for which these medications were prescribed. The intent of the
teacher interview was to obtain information comparable to that secured from parents
to determine the degree of agreement about the goals and efficacy of treatment.
Additionally, the study investigated 1) the combinations of psychotropic medications
that students currently are receiving, 2) the behavioral domains that those medications
are intended to affect, 3) the current status of those behavioral domains, and 4)
consumers' satisfaction with the pharmacological intervention.

METHOD
Participants and Setting
Information was collected regarding medication usage in 21 school-aged
children identified by school nurses and teachers. These students attended three
different school districts in two small Midwestern cities. Each student had a
diagnosis of mental retardation and/or autism and was currently receiving one or
more psychotropic medications. Seventeen of these students attended a center-based
program, one student attended an elementary school and three students attended a
middle school. The students in the elementary and middle schools received special
education services and attended some general education classes.
Written notification was sent home with all of these students requesting
parents/guardians permission for the investigator to contact them (See Appendix A).
Interested parents/guardians contacted the student's teacher or school psychologist
via phone call or written permission, who provided the investigator with the
parent's/guardian's identifying information. The investigator contacted these
parents/guardians via phone call and an interview time was arranged. Twenty-one
parents/guardians consented to an interview.
After the completion of the parent/guardian interview, the student's primary
teacher was contacted via phone call and an interview time was arranged. Fourteen
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teachers consented to an interview. Ten teachers were employed by a center-based
program, one teacher was employed at an elementary school, and two teachers were
employed at a middle school. Six teachers were interviewed for multiple students.
Information for each student was provided by only one teacher.
Procedure
Interviews took approximately 15 minutes during which the parents/guardians
and teachers completed a brief questionnaire. Parent/Guardian interviews were
conducted in the family's home, at a designated meeting place or by phone. Consent
was obtained at the onset of the interview (See Appendix B). Consent also was
obtained for the investigator to contact the child's primary teacher and conduct a
similar interview. Teacher interviews were conducted at the relevant school. Consent
was obtained at the onset of the interview (See Appendix C). The investigator asked
all of the questions in a semi-structured interview format.
Instrument
The instrument used in the semi-structured interview comprised two sections
(See Appendix D, E, F). The first section, displayed in Figure 1, requested: a)
information pertaining to current medication monitoring systems; b) information
about the student's prescribed medication; c) information regarding knowledge about
the intended effects of the medication; and d) information about the degree of
satisfaction with the drug treatment that the student currently is receiving.
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Figure I
Medication Information Form
Questions

1. What medication is this child currently taking to improve his/her mood,
2. cognitive status, or behavior?
3. How much ofthis medication does this child take each day?
4. How long has this child been taking this medication?
5. Do you know the potential side effects for this medication (Yes or No)

1. How satisfied are you with your current method of evaluating the
medication(s) listed above?
D I am very satisfied
D I am somewhat satisfied
D I am not at all satisfied
2. How satisfied are you with the results produced by the medication listed
above?
D I am very satisfied
D I am somewhat satisfied
D I am not at all satisfied
3. How much do you know about the changes in mood, cognitive status, and
behavior that the medication listed above should produce?
D I know a great deal
D I know a moderate amount
D I know a moderate amount or nothing
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The second section, displayed in Figure 2, included questions ascertaining
parent/guardian and teacher knowledge about whether the medication was prescribed
to treat behaviors in each of the five general domains for which psychotropic
medications are commonly prescribed for people with mental retardation (Aman &
Singh, 1986), whether these behaviors were being monitored in any manner; the
current status of those behavioral domains, and; whether there was any
communication between the school personnel, parents/guardians, and physicians
regarding the status of the behavior and/or efficacy of the medication. The behavioral
domains of interest were: a) irritability, agitation and crying (domain D; b) lethargy
and social withdrawal (domain II); c) hyperactivity and noncompliance (domain III);
d) stereotypic behavior (domain IV), and; e) inappropriate speech (domain V). Along
with the questions listed in Figure 2, the teacher form included two additional
questions ascertaining if they provided any information about the students behavior to
the parent/guardian or to the physician.

Figure 2
Behavioral Domain Information Form
Was a medication
prescribed to deal
with this kind
of behavior?

YES NO Don't Know
Kind of Behavior
I. Irritability, Agitation, and Crying
Examples of such behavior include, but are not limited to:

•
•
•
.•

□

□

0

□

D

□

YES NO Don't Know

Are you keeping
track of this kind
of behavior?
YES

NO

□

□

□

□

□

□

□

□

□

□

□

□

□

CJ

□

□

□

Hurting himself/herself deliberately
Being aggressive to other children
Crying or screaming_ at inappropriate times
Having temper outbursts or tantrums when s/he does
not get his/her own way

D. Lethargy and Social Withdrawal

Examples of such behavior include, but are not limited to:
•
•
•
•
•

Being sluggish and inactive
Seeking isolation from others
Resisting physical contact
Being unresponsive to structured activities
Preferring to be alone

III. Hyperactivity and Noncompliance

Examples of such behavior include, but are not limited to:
•
•
•
•
•

□

Is this kind of behavior
a problem at the
present time?

Acting without thinking first
Not sitting still for a reasonable length of time
Being disobedient or difficult to control
Failing to pay attention to instructions
Fidgeting and moving around

�

Figure 2 - Continued
Was a medication
prescribed to deal
with this kind
of behavior?

YES
Kind of Behavior
□
IV. Stereotypic Behavior
Examples of such behavior include, but are not limited to:
• Moving hand, body, or head repeatedly
• Waving or shaking the extremities repeatedly
• Rocking body back and forth repeatedly

V. Inappropriate Speech
Examples of such behavior include, but are not limited to:
• Talking excessively
• Talking loudly to him/herself
• Repeating a word or phrase over and over

□

NO

□

□

Don't Know

Is this kind of behavior
a problem at the
present time?

□

YES

NO

□

□

□

□

□

Don't Know

. Are you keeping
track of this kind
of behavior?

□

Y ES

□

NO

□

□

□

□

V,

RESULTS.
Section I
Parents/Guardians
Medication Report. The medications that students were prescribed are
displayed in Table 1. Students received anywhere from one to seven prescribed
psychotropic medications. Of the twenty-one students, 23% (N = 5) received one
medication, 19% (N = 4) received two medications, 23% (N = 5) received three
medications, 14%'(N = 3) received four medications, 5% (N = 1) received five
medications, 10% (N = 2) received six medications, and 5% (N = 1) received seven
medications. The two most commonly prescribed medications were the antipsychotic
risperidone (Risperdal) and the antihypertensive katapres (Clonidine).
Side effects. The results of the parent's/guardian's knowledge of side effects
are displayed in Table 2. Fifty-seven percent (N = 12) of the parents/guardians were
familiar with the side effects of at least one of the prescribed medications. Thirty
eight percent (N = 8) were familiar with all of the side effects of the prescribed
medications.
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Table I
List of Student's Prescribed Medications
Student

Medi

MedII

MedIII

Student l

catapres
(Clonidine)

risperidone
(Risperdal)

amphetamine
(Adderal)

Student 2

valproic acid risperdone
(Risperdal)
(Depakote)

Student 3

lamotrigine
(Lamictal)

phenytoin
(Dilantin)

Student 4

buspiron
(Buspar)

methylphenidate
(Ritalin)

Student 5

fluoxetine
(Prozac)

lamotrigine
(Limictal)

Student 6

sertraline
(Zoloft)

catapres
(Clonidine)

Student 7

trazadone
(Deseryl)

MedIV

MedV

MedVI

MedVII

benzotropine eskalith
(Cogentin) (Lithium Carbonate)
(Lonegran)

quetiapine
(Seroquil)

fluvoxamine topiramate
(Luvox)
(Topomax)

trazadone
(Deseryl)

Table 1 - Continued
MedIV

topiramate
(Topomax)

valproic acid venlafazine
(Depakote) (Effexor)

Medi

MedII

Student 8

sertraline
(Zoloft)

catapres
(Clonidine)

Student 9

quetiapine
(Seroquil)

Student 10

sertraline
(Zoloft)

risperidone
(Risperdal)

Student 11

phenytoin
(Dilantin)

valproic acid gabapentin
(Depakote) (Neurotin)

Don't Know

(Geodon)

gabapentin
(Neurotin)

catapres
(Clonidine)

Student 12
Student 13

catapres
(Clonidine)

Student 14

methylphenidate
(Ritalin)

Student 15

trazadone
(Deseryl)

MedV

MedIII

Student

risperidone
(Risperdal)

benzotropine quetiapine
(Cogentin)
(Seroquil)

MedVI

MedVII

eskalith
(Lithium Carbonate)

benzotropine dextroamphetamine
(Adderall)
(Cogentin)

fluvoxamine dextroamphetamine
(Dexedrine)
(Luvox)

Table 1 - Continued

MedIV

MedII

MedIII

lorazepam
(Ativan)

risperidone
(Risperdal)

carbamazepine
(Tegretol)

Student 18

catapres
(Clonidine)

olazapine
(Zyprexa)

methylphenidate
(Concerta)

Student 19

haloperidol
(Haldol)

benzotropine lorazepam
(Congentin) (Ativan)

Student 20

risperidone
(Risperdal)

hydroxyzine methylphenidate
(Atarax)
(Ritalin)

Student 21

catapres
(Clonidine)

lorazepam
(Ativan)

Student

MedI

Student 16

risperidone
(Risperdal)

Student 17

carbamazepine
(Tegretol)

valproic acid
(Depakote)

MedV

MedVI

MedVII
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Table2
Parents/Guardians Knowledge of Psychotropic Medication Side Effects

Student

No. of prescribed
medications

No. of medications with
knowledge of side effects

Student1

3

3

Student2

4

4

Student3

7

0

Student4

2

l

Student5

2

0

Student6

2

l

Student7

1

l

Student 8

2

0

Student 9

1

0

Student10

6

1

Student11

4

4

Student12

6

0

Student13

1

0

Student14

1

1

Student15

5

4

Student16

1

1

Student17

3

3
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Table 2 - Continued

Student

No. of prescribed
medications

No. of medications with
knowledge of side effects

Student 18

3

0

Student 19

4

0

Student 20

3

2

Student 21

3

3

Satisfaction. The parent/guardian satisfaction with current methods of
evaluating the medication(s), satisfaction with the results of the medication(s) and
knowledge about the changes produced by the medication(s) are displayed in Figure
3. In general, reports were mixed. That is, while the majority of parents/guardians
reported being satisfied with their current method of evaluating the medication(s),
they were mixed with being satisfied and not satisfied with the results of the
medication, and the majority reported knowing a moderate amount about changes
produced by the medication(s).
Teachers
Satisfaction. The teacher satisfaction with current methods of evalua�ng the
medication(s), satisfaction with the results of the medication(s) and knowledge about
the changes produced by the medication(s) are displayed in Figure 3. Unlike the
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Figure 3
Parents/Guardian and Teacher Satisfaction with Current Methods of
Evaluating the Medication(s), Satisfaction with the Results of the
Medication(s) and Knowledge About the Changes Produced
by the Medication(s)
Parents/Guardian
How satisfied are you with your
current method ofevaluating the
medication(s) listed above?
Number of responses

Teachers
How satisfied are you with your current
method of evaluating the medication(s)
listed above?
Number of responses

4 7% I am very satisfied
28% I am somewhat satisfied
24% I am not at all satisfied

14% I am very satisfied
9% I am somewhat satisfied
61% I am not at all satisfied

How satisfied are you with the
results produced by the medication
listed above?

How satisfied are you with the results
produced by the medication listed above?

Number of responses

38% I am very satisfied
24% I am somewhat satisfied
38% I am not at all satisfied
How much do you know about the
changes in mood, cognitive status,
and behavior that the medication
listed above should produce?
Number of responses

28% I know a great deal
4 7% I know a moderate amount
19% I know a moderate amount or
nothing

Number of responses

14% I am very satisfied
47% I am somewhat satisfied
28% I am not at all satisfied
How much do you know about the changes
in mood, cognitive status, and behavior that
the medication listed above should produce?
Number of responses

0% I know a great deal
14% I know a moderate amount
76% I know a moderate amount or
nothing
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parents/guardian, the teachers were not satisfied with the medication evaluation
process. Additionally, 76% of teachers indicated knowing a moderate amount or
nothing about the changes in mood, cognitive status and behavior that the
medication(s) prescribed should produce.
Section II
Parent/Guardian
Domain knowledge. The results of parents/guardians knowledge about the
domains for which the medication was prescribed indicate that medication was most
often prescribed for irritability, agitation, and crying followed by hyperactivity and
noncompliant behaviors. Seventy-one percent (N = 15) indicated that their child was
prescribed a medication targeting irritability, agitation and crying. Of this 71%, 66% (N =
10) indicated that these kinds of behaviors are a problem at the present time and 60% (N
= 6) of these parents/guardians are keeping track of these behaviors in some manner.
Sixty-six percent (N = 14) of parents/guardians indicated that their child was
prescribed a medication targeting hyperactivity and noncompliance behaviors. Of this
66%, 35% (N = 5) indicated that these kinds of behaviors are a problem at the present
time and 40% (N = 2) of these parents/guardian are keeping track of this behavior in
some manner.
Four percent (N = 1) reported that their child was prescribed a medication
targeting lethargy and social withdrawal and 9% (N = 2) reported that their child was
prescribed a medication targeting stereotypic behavior. No parents/guardians reported
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that their child was prescribed a medication targeting inappropriate speech.
Teachers
Domain knowledge. The results of the teacher knowledge about the domains for
which the medication was prescribed indicate that many of them did not know the
behaviors targeted by the medication. Forty-seven percent (N = 9) of teachers indicated
that medication was prescribed for irritability, agitation and crying behaviors and 52% (N
= 10) reported that medication was prescribed for hyperactivity and noncompliance
behavior. However, 31% (N = 6), 47% (N = 9), 36% (N = 7), 42% (N = 8), and 42% (N =
8) indicated that they did not know if a medication was prescribed for irritability,
agitation and crying behaviors, lethargy and social withdrawal behavior, hyperactivity
and noncompliance behavior, stereotypic behavior, or inappropriate speech behavior,
respectively.
Fifty-seven percent (N = 11) of teachers indicated that irritability, agitation and
crying behaviors were a problem at the present time and 57% (N = 11) indicated that
inappropriate speech behaviors were a problem at the present time. All of the teachers
that were monitoring behaviors also were providing parents/guardians with the
monitoring information. There were teachers, however, who were not monitoring
relevant behaviors, but were still providing parents/guardians with information about
these behaviors (See Table 3). That is, the teacher would not be systematically
monitoring the behavior, but would inform the parents/guardians about the status of
important behaviors. For example, if a student displayed incidents of self-injurious
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behavior (SIB), the teacher would not inform the parent of the number of times the SIB
occurred. The teacher would report that the student had a "good day" or a "bad day" with
regards to SIB behavior. This generic information, however, does not indicate what
constitutes as a good or bad day. It only indicates whether the behavior occurred or did
not occur. All but one of the teachers indicated not being directly involved in providing
the physician with any information. One teacher accompanies the parent to the physician
appointments. Additionally, one teacher indicated writing
reports for the parents to take to the physician.

Table 3
Teachers Not Systematically Monitoring Behavior but Providing Global
Information to Parents/Guardian About Behavior
Domain Type

Percentage of Teachers

Domain I

42% (N=8)

Domain II

36%(N=7)

Domain ill

47%(N=9)

Domain IV

42%(N=8)

Domain V

31%(N=6)

Overall, there were 28 different.psychotropic medications and 8 different drug
classes prescribed for the students (See Table 4). Table 5 specifies the students and the
behaviors the medications were prescribed to target. Comparing the results from tables 1,
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4, and 5 shows that several of the medications were prescribed for an off-label usage.
Medications that are approved for dispersement have specific conditions for which they
have been proven to be effective (See Table 4). When a medication is used for a
condition for which it has not been approved, it is said to be an off-label use of the
medication. That is, the FDA has not approved the medication for the prescribed
rationale. For example, student 13 was prescribed catapres to target hyperactive and
noncompliant behaviors, however, this medication is only indicated for use in the
treatment of hypertension. Student 18 was prescribed catapres, olazapine, and
methylphenidate to target irritability, agitation, crying, hyperactive, and noncompliant
behaviors, however, catapres is only indicated for use in the treatment of hypertension
and olazapine is only indicated for use in the management of psychotic disorders. Student
20 was prescribed risperidone, to target irritability, agitation, crying, hyperactivitive, and
noncompliant behaviors, however, risperidone is only indicated for the use in the
management of psychotic disorders.
When physicians prescribe a psychotropic medication for an off-label use they are
in essence conducting a mini-experiment. That is, the physician is hypothesizing that
administering a specific drug will produce a desired effect (Sprague and Werry, 1971).
In such cases, it is essential that sufficient data be collected to confirm or reject this
hypothesis. Moreover, to ensure appropriate off-label usage of drugs, physicians must be
familiar with current research and established usage of medications because as indicated
earlier, parents will depend on them to diagnose problems and prescribe medications
without understanding the consequences of administering such medication (Werry 1999).
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Polyphannacy is also a concern with many of the students. Polyphannacy is the
simultaneous use of two or more drugs of the same basic type. For example, both student
3, and student 15 were prescribed two antidepressant medications, (i.e., fluvoxamine and
trazadone). According to Bates, Smeltzer, and Arnoczky (1986) polyphannacy "is always
inappropriate because it involves increased risk without likelihood of increased benefit"
(p. 365).
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Table 4
Frequency of Medications Prescribed and Approved Usage
Major Groupings/
Specific Drugs

Antianxiety Drugs
hydroxyzine (Atarax)
lorazepam (Ativan)
buspiron (Buspar)
Antidepressant Drugs
fluoxetine (Prozac)
fluvoxamine (Luvox)
sertraline (Zoloft)
trazadone (Deseryl)
venlafazine (Effexor)
Anticholinergic Drugs
benzotropine (Cogentine)
Antiepileptic Drugs
carbamazepine (Tegretol)
gabapentin (Neurotin)
lamotrigine (Larnictal)
phenytoin (Dilantin)
topiramate (Topomax)
valproic acid (Depakote)
Antihypertensive Drugs
catapres (Clonidine)

Frequency

Approved Usage

1
3
1

Management of anxiety disorders or for the
short-term relief of the symptoms of anxiety
or anxiety associated with depressive
symptoms

1
2
3
3
1

Treatment of depression, obsessions and
compulsions in persons with obsessive compulsive.
disorder, panic disorder, and binge-eating and
vomiting behaviors in patients with moderate to
severe bulimia nervosa. Trazadone and venlafazine
are for the treatment of depression only.

4

2
2
2
2
2

4

7

Use as an adjunct in the therapy of all forms
of parkinsomism and for control of EPS due
to neuroleptics.
Treatment of seizures.
The safety and effectiveness of the use of
larnictal in children below the age of 16 has
not been established.
Depakote is also used to control manic
episodes that occur in bipolar disorder.
Treatment of hypertension
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Table 4 - Continued
Major Groupings/
Specific Drugs
Antipsychotic Drugs
haloperidol (Haldol)
olazapine (Zyprexa)
quentiapine (Seroquel)
risperidone (Risperdal)

Frequency

1
1
3
7

Approved Usage

Use in management of manifestation of psychotic
disorders, for the control of tics and vocal
utterances of Tourette's disorder, treatmentof
severe behavior problems in children, and
treatment of hyperactive children (Note: Should
be reserved for these last two groups of children only
after failure to respond to medication other than
antipsychotics). Olazapine, risperidone, and
quetiapine are for use in the management of
psychotic disorders only.

Antimanic Drugs
eskalith (Lithium Carbonate) 2

Treatment of manic episodes of manic-depressive
illness.

Stimulant Drugs
dextroamphetamine
(Adderall, Dexedrine)
methylphenidate
(Concerta, Ritalin)

Treatment of attention deficit hyperactive
disorder; Narcolepsy.

3
4
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Table 5
Parents Indication of the Behaviors Targeted for Prescribed Medications

Student

Target Behaviors

Student 1

irritability, agitation, crying, hyperactivity, and noncompliance

Student 2

irritability, agitation, crying, and Schizo_ Affective Disorder

Student 3

Do not know

Student 4

irritability, agitation, crying, hyperactivity, and noncompliance

Students

irritability, agitation, and crying

Student 6

irritability, agitation, crying, lethargy, social withdrawal,
hyperactivity, noncompliance, and to help sleep

Student 7

irritability, agitation, and crying

Student 8

hyperactivity, and noncompliance

Student 9

irritability, agitation, crying, hyperactivity, and noncompliance

Student 10

Do not know

Student 11

Mainly for seizures, aggression

Student 12

Schizophrenia, to help sleep, irritability, agitation, crying,
hyperactivity, noncompliance, and stereotypic behavior

Student 13

hyperactivity and noncompliance

Student 14

hyperactivity and noncompliance

Student 15

ADHD, aggression, sexual deviancy, and sleep

Student 16

irritability, agitation, and crying
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Table 5 - Continued
Student

Target Behaviors

Student 17

irritability, agitation, and crying

Student 18

irritability, agitation, crying, hyperactivity, and noncompliance;
supposed to calm him down

Student 19

irritability, agitation, and crying; hyperactivity and noncompliance

Student 20

irritability, agitation, crying, hyperactivity, and noncompliance

Student 21

hyperactivity and noncompliance

DISCUSSION
Discussion
The results of this study suggest that both at home and at school there is a lack
of systematic monitoring of the effects of psychotropic medications. While a high
percentage of parents/guardians indicated that they were satisfied with the current
method of evaluating their child's medications, none of them employed a systematic
monitoring system. That is, a number of parents/guardians mentioned they had a
journal that they used to track medication changes, (i.e., increases or decreases in
dosage level or addition of new medication), but none of them monitored the number
of occurrences of targeted behaviors for which the medication was prescribed.
Consequently, the efficacy of the psychotropic medication is not being evaluated
systematically. A number of parents/guardians did mention they might make note of
their general impressions of the child's behavior, which was later relayed to the
physician. One parent indicated that she independently adjusted her child's
medication based on her impressions of her child's status. For example, if she thought
her child's behavior warranted an increase in medication then she would call the
physician's office, inform them that the medication was being increased, and proceed
with adjusting the medication to a dosage she deemed appropriate. This parent also
noted that the call to the physician did not always occur before she increased the
medication dosage. In general, the findings of this survey concur with the results of
32
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previous research in suggesting that physician's decisions to change medication is not
based on related changes in the target behavior, but on global impressions by parents
and teachers (Singh & Winton, 1984; Fredericks & Hayes, 1995).
Additionally, the results suggest that teachers had a lack of knowledge
regarding the reasons for which students were prescribed medications and about what
medications the students received. Several teachers referred the interviewer to the
school nurse when queried about the exact medication a student received. This
suggests that if teachers are tracking behaviors targeted by the medication, they may
not know it. In such cases, data collected are not likely to be communicated to the
parents/guardians to be relayed to the physician.
The results further suggest that both the parents/guardians and teachers have a
lack of knowledge regarding the side effects of the medications prescribed. Forty
three percent of the parents/guardians did not know the side effects of all medications
and none of the teachers knew any of the side effects of the medications prescribed
for the students. The parents of student 3 and student 12 did not know any of the
listed side effects for any of the prescribed medications. These two students were
prescribed the largest number of medications.
The results of the survey indicated a lack of communication among teachers,
parents/guardians, and physicians with respect to information related to the student's
prescribed medication. Several teachers indicated they send home daily notes
providing global impressions about the student's behavior. However, these notes may
not indicate impressions relevant to the behavior targeted by the medication.
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In general, it was the researcher's impression that the parent's/guardian's
knowledge about their child's behavior was often related to the intensity of the child's
behavior problems, but not the socioeconomic status, education level, or school
district. For example, one parent, a single mother, appeared to the researcher to not
have much by way of economic resources. She resided in a low-income neighborhood
and accessed state-funded waver services for assistance with her child, who displayed
intense aggressive behaviors and required one-on-one care at school. This parent,
however, was fully knowledgeable of all of her child's prescribed medications,
reasons for the medication and the side effects. She monitored her child's behavior
and kept a journal of the child's medication changes and physician appointments. She
also communicated regularly with the school about her child's behavioral status.
Another parent, a mother, who was married and resided in an affluent neighborhood,
did not appear to have as much knowledge about her child's prescribed medications,
the reasons for the use of medication, and it's side effects. This parent did not monitor
her child's behavior and communicated infrequently with the school about her child's
behavioral status.
There were some general limitations to the current study. The most important
one is that the participants selected for this study are a small and nonrandom sample
of the population of parents whose school-aged children have a diagnosis of mental
retardation and/or autism and currently receiving one or more psychotropic
medications. Thus, a generality of the present results is limited. Another: limitation is
that the survey form did not directly query the parents/guardians requesting whether
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their child had a specific psychiatric or medical diagnosis. It only asked what
behaviors the medications were prescribed to address. Knowledge regarding
diagnostic labels would have been helpful for reporting ifthe medications were
prescribed for an off-label use. That is, ifa student were prescribed catapres, it would
be useful to know ifs/he had a diagnosis of hypertension or a psychotic condition
(e.g., schizophrenia). A third limitation is the language ofthe survey may have been
difficult for respondents to understand. For example, one parent requested that the
researcher read the survey to her.
Future Directions
Because ofthe high number ofpsychotropic medications prescribed to school
aged children, systematic monitoring ofthe effects ofthese medications could be very
valuable. In this regard, first, teachers need to be better informed ofwho in their class
is talcing medications. Currently, parents are not required to inform the school
personnel iftheir child is prescribed a medication. This information is only required
ifa dosage administration is necessary during the school day. Also, parents are not
required to inform school staff ifthere is a decrease or increase in medication dosage.
Again, this information is only required ifit pertains to the dosage administered at the
school.
Second, school personnel (i.e., teachers, school psychologists, social workers)
need to become better informed regarding the effects ofcommonly prescribed
medications. They should acquire knowledge about the rationale for their use, effects
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on academic and social behavior, and common side effects. Such knowledge could be
provided through required in-service trainings, with information presented at a level
that is understandable by all who attend.
Third, school personnel should be trained on how to monitor systematically
the behaviors that medications are prescribed to target. Monitoring should occur
before, during, and after the use of drug therapies. Fourth, school personnel should
take the initiative in establishing policies for ensuring that the data they collect are
communicated to parents and physicians.
Finally, monitoring of the effects of all psychotropic medication is likely to be
needed if substantial progress is to occur. As previously discussed, medication usage
in institutions did not change until laws were established regulating its usage. It
would seem that if schools personnel and physicians were required by law to monitor
systematically the effects of psychotropic medications prescribed for school-aged
children, this would be a major step in the right direction.
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Dear Parent,
We are faculty members and students in the Department of
Psychology at Western Michigan University. We are doing
research to find out what types of medication monitoring
procedures are being used in school and at home for children
with developmental disabilities who are receiving psychotropic
medications. The goal of our research is to help parents and
school staff to develop an effective and practical medication
monitoring system.
We will be contacting you by phone within the next two
weeks and providing further details about this research project.
If you would like to speak with someone immediately, please
feel free to contact one of us at the numbers listed below, or you
may speak with Sandy Beiter, R.N., B.S.N., N.S.C.N., your
child's school nurse, at 373-3275.
Al Poling, Ph.D.
Professor
387-4483

Kristal Ehrhardt, Ph.D.
Professor
387-4478

Lynne Turner
Doctoral Student
387-4560

Lanai Jennings
Doctoral Student
387-4560
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Appendix B
Parent Consent Form
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Western Michigan University
Department of Psychology
Principal Investigator: Alan Poling & Kristal Ehrhardt
Research Associate: Lynne Turner & Lanai Jennings
Parent Permission
I have been invited to participate in a research project entitled "Monitoring of
Psychotropic Medication at School and at Home". The purpose of the study is to
evaluate how medication is monitored in the schools and at home and to establish an
ongoing monitoring system if one is not currently in place. This project is being
conducted to fulfill Lynne Turner & Lanai Jennings' theses requirements.
This project will be conducted in two phases. I agree in the first phase to be
interviewed to complete a brief questionnaire. The questionnaire includes questions
about my child's current medication and my satisfaction with this medication. The
interview will take no more than 60 minutes to complete. I also agree in the second
phase to monitor my child's behaviors and side effects by completing either the
Aberrant Behavior Checklist and the Detection of Side Effects Scale (15 minutes
total) or a condensed version of the scales. Phase two will involve 13 weekly
sessions, each lasting no more than 20 minutes. Phase two may also entail a single
problem-solving interview lasting 30-60 minutes.
My permission also means that my child's teacher may be contacted for an interview
to complete a similar questionnaire about my child's medication and behavior in the
classroom. In addition, my permission serves as a release allowing the researchers to
access confidential medical information from the school nurse and my child's
physician regarding my child.
The interview responses will be confidential. This means that my child's name will
be omitted from all forms and a code number will be attached. The principal
investigator will keep a separate master list with the names of the children and the
corresponding code numbers. Once the data are collected and analyzed, the master
list will be destroyed. All other forms will be retained for three years in a locked file
in the principal investigator's office. No names will be used if the results are
published or reported at a professional meeting.
If I chose to participate, I may gain knowledge about the effects of the medication
that my child is taking. Additionally, I may find that my child's medication is being
used appropriately.
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If I choose to participate, I may find that I am dissatisfied with the medication my
child is prescribed. However, it is not the researchers' purpose to bring about
changes in medication, but to monitor the effects of prescribed medication. If I am
unhappy with my child's medication at any time, I should consult with my child's
physician to share my concerns before making any changes to my child's treatment.
As in all research, there may be unforeseen risks to the participant. If an accidental
injury occurs, appropriate emergency measures will be taken; however, not
compensation or additional treatment will be made available to the subjects except as
otherwise stated in this consent.
I am free to terminate my involvement in the project at any time during either phase
one or phase two. If I choose to terminate my involvement, there will be no negative
consequences or penalties and my choice will not affect my child's enrollment in the
K/RESA school system. Ifl have any questions, I may contact Lynne Turner and
Lanai Jennings at 387-4650, Kristal Ehrhardt at 387-4478 or Alan Poling 387-4483. I
may also contact the chair of the Human Subject Institutional Review Board at 3878293 or the Vice President for Research at 387-8298 with any concerns that I have.
This permission document has been approved for use for one year by the Human
Subjects Institutional Review Board as indicated by the stamped date and signature of
the board chair in the upper right comer. Subjects should not sign this document if
the comer does not have a stamped date and signature

Date

Time

You are making a decision whether or not to participate. Your signature indicates
that you have decided to participate having read the information provided above.

Signature of Parent/Guardian

Signature of Investigator
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Appendix C
Teacher Consent Form
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Western Michigan University
Department of Psychology
Principal Investigators: Alan Poling and Kristal Ehrhardt
Research Associates: Lynne Turner and Lanai Jennings
Teacher Permission
I have been invited to participate in a research project entitled "Monitoring of
Psychotropic Medication at School and at Home". The purpose of the study is to
evaluate how medication is monitored in the schools and at home and to establish an
ongoing monitoring system if one is not currently in place. This project is being
conducted to fulfill Lynne Turner and Lanai Jennings' theses requirements.
This project will be conducted in two phases. I agree in the first phase to be
interviewed to complete a brief questionnaire that includes questions about (name of
child)'s current medication and behavior. The interview will take no more than 60
minutes to complete. I also agree in the second phase to monitor student behaviors
and side effects by completing either the Aberrant Behavior Checklist and the
Detection of Side Effects Scale (15 minutes total) or a condensed version of the
scales. Phase two will involve 13 weekly sessions, each lasting no more than 20
minutes. Phase two may also entail a single problem-solving interview lasting 30-60
minutes.
The interview responses will be confidential. This means that your name and the
student's name will be omitted from all forms and a code number will be attached.
The principal investigator will keep a separate master list with the names of the
children and the corresponding code numbers. Once the data are collected and
analyzed, the master list will be destroyed. All other forms will be retained for three
years in a locked file in the principal investigator's office. No names will be used if
the results are published or reported at a professional meeting.
If I chose to participate, I may gain knowledge about the intended effects of the
medication that my student is taking: I will also have the opportunity to provide
critical feedback to the investigators about monitoring medication in school settings.
My feedback may facilitate changes that would make such a monitoring system more
feasible for teachers like myself to implement.
If I choose to participate, I may find that I am dissatisfied with the medication my
student is prescribed. However, it is not the researchers' purpose to bring about
changes in medication, but to monitor the effects of prescribed medication.
I am free to terminate my involvement in the project at any time during either phase
one or phase two. Doing so will have no negative consequences or penalties,

although, there is a possibility that the student's parents may be upset with my
decision.
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Ifl have any questions, I may contact Lynne Turner at 387-4650, Lanai Jennings at
387-4345, Kristal Ehrhardt at 387-4478 or Alan Poling at 387-4483. I may also
contact the chair of the Human Subject Institutional Review Board at 387-8293 or the
Vice President for Research at 387-8298 with any concerns that I have.
This permission document has been approved for use for one year by the Human
Subjects Institutional Review Board as indicated by the stamped date and signature of
the board chair in the upper right corner. Subjects should not sign this document if
the corner does not have a stamped date and signature

Date

Time

You are making a decision whether or not to participate. Your signature indicates
that you have decided to participate having read the information provided above.

Signature of Parent/Guardian

Signature of Investigator
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Appendix D
Medication Information Form

Child's Name:----------

Respondant: __________
Medi

Med II

Med Ill

Med IV

MedV

What medication is this child currently
taking to improve his/her mood,
coanitive status, or behavior?
How much of this medication does
this child take each day?
How long has this child been
taking this medication?
Do you know the potential side effects
for this medication? YES or NO
Please answer the following questions with respect to your child.
How satisfied are you with your current method of evaluting the medication(s) listed above?

□ I am very satisfied
□ I am somewhat satisfied
□ I am not at all satisfied

How satisfied are you with the results produced by the medication listed above?

□ I am very satisfied
□ I am somewhat satisfied
□ I am not at all satisfied

How much do you know about the changes in mood, cognitive status, and behavior that the medication listed above should produce?

o I know a great deal
o I know a moderate amount
o I know a moderate amount or nothing

Are you interested in developing a system for systematically monitoring medication effects?
□ Yes
□ No
□ Undecided

V,
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Appendix E
Teacher Interview Form

Behavioral Domain Information Form
Teacher and Nurse Version

Kind of Behavior

I. Irritability, Agitation, and Crying

Was a medication
Prescribed to deal
With this kind
of behavior?

Is this kind of
behavior a problem
at the present time?

YES NO Don't Know

YES NO Don't Know

□ □

□

□ □

□

Examples of such behavior include, but are not limited to:
• Hurting himself/herself deliberately
• Being aggressive to other children
• Crying or screaming at inappropriate times
• Having temper outbursts or tantrums when s/he does
not get his/her own way

II. Lethargy and Social Withdrawal

Examples of such behavior include, but are not limited to:
• Being sluggish and inactive
• Seeking isolation from others
• Resisting physical contact
• Being unresponsive to structured activities
• Preferring to be alone

□ □

□

□ □

□

If yes,
Are you
e you
Are you keeping g1vmg
giving the
track of this kind parents the physician the
of behavior?
information? information?
YES

□

NO

□

□ □

YES

NO

□ □

□ □

----------------------------------1-----------i--------f--------1

III. Hyperactivity and Noncompliance

□ □

Examples of such behavior include, but are not limited to:
• Acting without thinking first
• Not sitting still for a reasonable length of time
• Being disobedient or difficult to control
• Failing to pay attention to instructions
• Fidgeting and moving around

□

□ □

□

□

□

□ □

ES

NO

□ □

□ □

□ □
V,
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Behavioral Domain Infonnation Form
Teacher and Nurse Version

Kind of Behavior

IV. Stereotypic Behavior

Was a medication
Prescribed to deal
With this kind
of behavior?

Is this kind of
behavior a problem
at the present time?

YES NO

YES NO Don't Know

□ □

Examples of such behavior include, but are not limited to:
• Moving hand, body, or head repeatedly
• Waving or shaking the extremities repeatedly
• Rocking body back and forth repeatedly

V. Inappropriate Speech

□

Examples of such behavior inplude, but are not limited to:
• Talking excessively
• Talking loudly to him/herself
• Repeating a word or phrase over and over

□

Don't Know

□

□

□ □

□

□ □

□

If yes,
Are you
e you
Are you keeping giving
giving the
track of this kind parents the physician the
information? information?
of behavior?
YES

□

□

NO

□

□·

YES

NO

□

□

□ □

YES

NO

□ □

□ □

�
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Appendix F
Parent/Guardian Interview Form

Kind of Behavior

Behavioral Domain Information Form
Parent Version
Was a medication
prescribed to deal
Is this kind of behavior
with this kind
a problem at the
of behavior?
present time?

I. Irritability, Agitation, and Crying

YES NO Don't Know

Examples of such behavior include, but are not limited to:
• Hurting himself/herself deliberately
• Being aggressive to other children
• Crying or screaming at inappropriate times
• Having temper outbursts or tantrums when s/he does
not get his/her own way

II. Lethargy and Social Withdrawal
Examples of such behavior include, but are not limited to:
• Being sluggish and inactive
• Seeking isolation from others
• Resisting physical contact
• Being unresponsive to structured activities
• Preferring to be alone

III. Hyperactivity and Noncompliance
Examples of such behavior include, but are not limited to:
• Acting without thinking first
• Not sitting still for a reasonable length of time
• Being disobedient or difficult to control
• Failing to pay attention to instructions
• Fidgeting and moving around

□

□

□ □

□

□

□

YES NO Don't Know

Are you keeping
track of this kind
of behavior?
YES

NO

□

□

□

□

□

□

□

□

□

□

□

□

□

□

□

□

□

°'
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Behavioral Domain Information Form
Parent Version

Kind of Behavior

IV. Stereotypic Behavior

Examples of such behavior include, but are not limited to:
• Moving hand, body, or head repeatedly
• Waving or shaking the extremities repeatedly
• Rocking body back and forth repeatedly

V. Inappropriate Speech

Examples of such behavior include, but are not limited to:
• Talking excessively
• Talking loudly to him/herself
• Repeating a word or phrase over and over

Was a medication
prescribed to deal
with this kind
of behavior?
YES

NO

□

□

□

□

Don't Know

□

□

Is this kind of behavior
a problem at the
present time?

Are you keeping
track of this kind
of behavior?

YES

NO

Don't Know

Y ES

NO

□

□

□

□

□

□

□

□

□

□
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Appendix G
Approval Letter From the Human Subjects Institutional Review Board

59

.. .

,··

! ,\ ·•

WESTERN MICHIGAN UNIVERSITY

Date: May 10, 2001
To:

Alan Poling, Principal Investigator
Kristal Ehrhardt, Co-Principal Investigator
Lanai Jennings, Student Investigator for specialist project
Lynne Turner, Student Investigator for thesis

From: Michael S. Pritchard, Interim Chair
Re:

'11Wj, �

HSIRB Project Number 01-02-13

This letter will serve as confinnation that your research project entitled "Practical Evaluation of
Psychotropic Medication" has been approved under the full category of review by the Human
Subjects Institutional Review Board. The conditions and duration of this approval are specified
in the Policies of Western Michigan University. You may now begin to implement the research
as described in the application.
Please note that you may only conduct this research exactly in the form it was approved. You
must seek specific board approval for any changes in this project. You must also seek reapproval
if the project extends beyond the termination date noted below. In addition if there are any
unanticipated adverse reactions or unanticipated events associated with the conduct of this
research, you should immediately suspend the project and contact the Chair of the HSIRB for
consultation.
The Board wishes you success in the pursuit of your research goals.
Approval Termination:

21 February 2002

